To evaluate immunoreactivity of cyclooxygenase-2 in cases of endometrial carcinoma and correlate it with expression of p53 and vascular endothelial growth factor

• Published in: Journal of cancer research and therapeutics Vol. 14; no. 6; pp. 1366 - 1372
• Main Authors: Sunita, B, Sen, Arijit, Suhag, Virender
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer India Pvt. Ltd 01.10.2018; Medknow Publications and Media Pvt. Ltd; Medknow Publications & Media Pvt. Ltd
• Subjects: Angiogenesis; Cancer; Cancer diagnosis; Cancer research; Carcinogenesis; Carcinogenesis - metabolism; Carcinoma; Care and treatment; Cell growth; COX-2 inhibitors; Cyclooxygenase 2 - metabolism; Cyclooxygenases; Development and progression; Endometrial cancer; Endometrial Neoplasms - metabolism; Endometrium - metabolism; Endothelial growth factors; Female; Gene expression; Genetic aspects; Gynecology; Health aspects; Health facilities construction; Humans; Immunohistochemistry - methods; Kinases; Lymphatic system; Medical prognosis; Metastasis; Mutation; Neoplasm Recurrence, Local - metabolism; Obstetrics; Prostaglandins; Retrospective Studies; Senators; Studies; Tumor proteins; Tumor Suppressor Protein p53 - metabolism; Tumors; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - metabolism; India; endometrial carcinoma; Cyclooxygenase-2; vascular endothelial growth factor; p53
• ISSN: 0973-1482; 1998-4138; 1998-4138
• DOI: 10.4103/0973-1482.202890

Context: Increased levels of prostaglandins have been detected in cancers of several anatomic sites, including those of endometrium. Several studies have shown that cyclooxygenase-2 (COX-2) expression is aberrantly increased in various human epithelial cancers, and cellular up-regulation of COX-2 may be a common mechanism in epithelial carcinogenesis. Aims: To examine the expressions of COX-2, p53 and vascular endothelial growth factor (VEGF) in endometrial cancer and their relationships with clinicopathologic characteristics. Setting and Design: A retrospective observational study in a tertiary care center of academic and research potential. Subjects and Methods: Sections from fifty cases of endometrial carcinoma were stained imunohistochemically with COX-2, p53, and VEGF. The expressions of COX-2, p53, and VEGF in endometrial cancer were examined. Results: COX-2 was positive 19 cases (38%) of endometrial carcinoma. The COX-2 immunopositivity was 50%, 28%, and 41% in Grade 1, Grade 2, and Grade 3; and 27%, 46%, 67%, and 100% cases of Stage I, II, III, IV, respectively. p53 was positive in 24 cases (48%); 0%, 33%, and 67% in Grade 1, Grade 2, and Grade 3; and 27%, 77%, 83%, and 100% cases of Stage I, II, III, IV, respectively. VEGF was positive in 21 cases (42%); of which 0%, 33%, and 67% cases were in Grade 1, Grade 2, and Grade 3; and 17%, 77%, 83%, and 100% cases were in Stage I, II, III, IV, respectively. Conclusion: The expression of COX-2 increase with stage of the endometrial tumor and with the expression of p53 and VEGF in the endometrial carcinomas. COX-2 inhibitors may have role in the prevention of endometrial carcinomas in high-risk cases and in preventing recurrences after treatment.